Soluble molecules and bone metabolism in multiple

myeloma: a review by Zoppoli, Gabriele et al.
Gabriele Zoppoli 
Enrico Balleari 
Riccardo Ghio 
Department of Internal Medicine (DIMI), 
Azienda Ospedaliera-Universitaria San Martino, 
University of Genoa, Italy
Address for correspondence: 
Gabriele Zoppoli, M.D.
Via Montello, 14/10 - 16137 Genova, Italy
Ph. +39 349 6170129
E-mail: gzoppoli@libero.it
Summary
Bone metabolism and turnover are strongly altered in multiple
myeloma, as a consequence of the proliferation of malignant
cells resembling plasmacells in the bone marrow. By both di-
rect or indirect secretion of several molecules, and cell-to-cell
interactions, multiple myeloma cells lead to severe and dis-
abling skeletal alterations, such as osteolytic lesions, patho-
logic fractures, and osteoporosis. In this review, we summa-
rize the studies concerning the soluble molecules which are
supposed to have a role in this pathological process. We then
consider the substances that, either in serum or urine speci-
mens, can be dosed in the affected patients, thus giving an in-
direct measure of their altered bone turnover. In the last part
of our review, we discuss the potential action of the new anti-
myeloma drug bortezomib (Velcade®, Janssen-Cilag), in op-
posing and maybe reverting, through a possible direct “pro-
osteoblastic” effect, the deranged bone turnover which char-
acterizes this disabling and unavoidably deathly disease. 
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Introduction
Multiple myeloma (MM) is a haematological neoplasia whose
hallmark is an abnormal proliferation of monoclonal cells re-
sembling mature plasmacells inside the bone marrow (1). MM
is characterized by skeletal alterations, such as bone pain, os-
teolytic lesions, pathologic fractures, and hypercalcemia (1-3).
Up to 80% of the patients experience these complications
sooner or later during the course of their disease (2). In pa-
tients affected by MM, osteoclastic activity enhancement (4-
16), paralleled by diminished osteoblastic function (6, 8, 9, 12,
15, 17-27), results in bone tissue rarefaction. This pathologic
process brings to focal osteolysis (the so-called “punched-out
lesions”) and to bone architecture generalized impoverishment,
namely, osteoporosis. Bone turnover is strongly altered in pa-
tients affected by MM. This phenomenon appears to be related
to both direct secretion of substances by MM cells and the al-
terations which occur in the microenvironment surrounding
them, following direct cell-to-cell interactions between malig-
nant cells and stromal ones. In these last few years research
efforts have been focused on the molecules acting in MM (4, 5,
7-11, 13, 17, 18, 21-25, 28-38), and on their effects towards
blocking osteoblastic activity and enhancing osteoclast-mediat-
ed bone resorption. Many of the investigated substances can
also be measured in urine or serum samples of the patients di-
agnosed with MM, along with bone turnover molecular by-prod-
ucts, and could prove to be useful markers for prognosis and
response to treatment (28, 39-52). So far, traditional agents
targeting MM cells were not able to restore normal bone
turnover, as they possess, with the possible exception of the
immunomodulatory drugs (IMiDs) thalidomide and lenalidomide
(Revlimid®, Celgene), a mainly cytolytic activity. Bisphospho-
nates have represented a step forward in preventing MM bone
complications, but this drug class does not enhance bone re-
generation. The first therapeutic molecule which could have di-
rect “pro-osteoblastic” properties is the proteasome inhibitor
bortezomib (Velcade®, Janssen-Cilag) (53-61). This review will
summarize the major advances in understanding the molecular
bases of the deranged bone turnover which characterizes MM,
with particular attention on the studies concerning the role of
soluble molecules in bone metabolism, and their possible role
in clinical practice. The potential of bortezomib to act on MM
deranged bone turnover will also be discussed.
Bone turnover in multiple myeloma
The pathogenesis of MM bone disease is complex: it encom-
passes both increased osteoclastic activation mechanisms,
and impaired osteoblastic function ones, thus leading to a sort
of “uncoupling” of the physiologic osteonic functional unit (6,
12, 14, 16, 62). The bone marrow microenviroment surround-
ing MM cells is made up of cells like fibroblasts, osteoblasts,
osteoclastic precursors, mature osteoclasts and endothelial
cells. Direct secretion of cytokines and other substances by
MM cells, and cell-to-cell interactions between neoplastic cells
and the surrounding environment, induce a distorted produc-
tion of osteoclast activating factors (OAFs). Amongst the most
investigated ones, there are molecules like Interleukin (Il)-1, 
Il-3, Il-6, Il-7, Il-11, Tumour Necrosis Factor (TNF)-α,
Macrophage Colony-Stimulating Factor (MCSF), PTH-related
Peptide (PTHrP), Hepatocyte Growth Factor (HGF),
Macrophage Inflammatory Protein (MIP)-1α, MIP-1β and Matrix
Metalloproteinases (MMPs) (4, 5, 11, 18, 31, 63). These fac-
tors are deemed to concur in raising the production of a major
osteoclastogenic factor, called receptor activator of NF-kB lig-
and (RANKL) (7), by both neoplastic and “by-stander” stromal
cells. Normally, RANKL and its “decoy” soluble receptor, Os-
teoprotegerin (OPG), keep under control bone resorption (15),
positively (RANKL) or negatively (OPG) regulating the growth
and activity of osteoclasts. MM cells break the balance be-
tween RANKL and OPG in favour of the first molecule (9, 10,
34, 50), possibly with a direct contribution to its secretion (13)
and to the degradation of OPG (34). As a consequence, MM
cells enhance the development, maturation and activity of the
osteoclasts, with a net increase in bone resorption (9, 10, 32,
35, 36).
On the other hand, both in vitro and ex vivo studies showed
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that, inside the bone milieu, MM cells act by decreasing the
number, activity and viability of osteoblasts, and by inducing
their apoptosis, via both direct interaction with these cells and
by secreting a number of inhibiting soluble factors (6, 17, 19,
20, 23, 26). Among the various molecular networks involved,
the inhibition of the Wingless-type (Wnt) signalling pathway
seems to play an important role in blocking osteoblastic sur-
vival and differentiation (64). This event may occur through the
abnormal secretion, by MM cells, of molecules such as Dick-
kopf (Dkk)-1 (21, 38) and Soluble Frizzle-Related Protein
(sFRP)-2 (25), which behave as Wnt pathway inhibitors. Other
soluble factors, like Il-7 and Il-3, were correlated, in vitro, with
osteoblastic differentiation arrest (17, 24), even though experi-
mental evidences about the occurrence of this phenomenon in
vivo are still lacking.
Clinical expressions of altered bone turnover
In serum or urine samples many substances, directly or indi-
rectly related to bone metabolism, can be quantified and are al-
tered in MM. For the sake of simplicity, and far from being ex-
haustive (since the number of discovered molecules in this field
is growing steadily), they can be classified and listed in four
broad groups, as follows:
1. Osteoclastic activity markers: serum Tartrate Resistant Acid
Phosphatase (TRAP)-5b (65), urinary or seric bone collagen
degradation products, like total Pyridinoline (T-Pyd), De-
oxypyridinoline (T-Dpd), cross linked N-telopeptide (Ntx), C-
telopeptide (Ctx) of type I collagen and immunologic free De-
oxypyridinoline (f-Dpd) (49), measurable in urinary samples, or
C-terminal and N-terminal Telopeptides of type I collagen (S-
CTX and S-NTX) and bone sialoprotein, which can be as-
sessed in serum specimens (thus circumventing some of the
limitations of urinary measurements) (41).
2. Osteoblastic activity markers: Osteocalcin (OC) (48), bone
Alkaline Phosphatase (bALP), Bone Morphogenetic Protein
(BMP)-2, which can be dosed in serum (30).
3. Molecules with inhibitory activity towards osteoblasts, or
whose decreased production ultimately results in impaired be-
haviour of osteoblasts: DKK-1 (21, 64), sFRP-2 (38), Il-3, Il-7
(23, 25), OPG reduced synthesis (these molecules can be
measured in serum samples too) (9, 10, 33, 34, 50).
4. Molecules with stimulating and activating properties towards
osteoclastic precursors and mature osteoclasts: Il-1, Il-3, Il-6,
Il-11, TNFα, MCSF, PTHrP, HGF, MIP-1α, MIP-1β, MMPs,
RANKL (serum samples) (4, 5, 11, 18, 31, 35, 37, 63).
Correlation between MM treatment and bone disease
During the last few years, many clinical studies assessed the
levels of various parameters of bone turnover, as the ones
summarized above, in patients with MM, finding the most of
them to be considerably altered. Their levels were often found
to correlate with activity, stage, or progression of MM (8, 28,
29, 36, 40, 42-45, 49, 51, 65-67), but so far none of them has
entered validated prognostic scores. The described bone me-
tabolism derangements provided the rational basis for treat-
ment of MM bone disease with bisphosphonates (68, 69).
These drugs act mainly by inhibiting osteoclasts (70), and pos-
sibly via a direct effect against MM cells (71, 72), but they are
not efficacious in restoring osteoblastic activity. Moreover, the
use of such agents is sometimes associated with severe com-
plications, like acute systemic inflammatory reactions, ocular
inflammation, renal failure, nephrotic syndrome, electrolyte im-
balance, and jaw osteonecrosis (73), so it is not advisable, ac-
cording to the available data, to prolong indefinitely therapy
with bisphosphonates. Few clinical studies were published,
which took into account different markers of bone resorption in
MM patients treated with various chemotherapeutic regimens
or with autologous stem cell transplantation. Some of them did
indeed show a reduction in indirect osteoclast activity indexes,
an amelioration of bone turnover markers, and modifications of
some of the aforementioned OAFs after treatment (38, 39, 46,
74). However, no traditional drug employed in MM therapy has
been linked with a direct activity on osteoblastic function so far.
Among the signalling pathways, considered as target candi-
dates of drugs in MM, the inhibition of degradation of ubiqui-
tinized proteins with molecules like bortezomib (75), which acts
by blocking the proteasome machinery, was found to be relat-
ed, both in in vitro (17, 27, 53, 58, 76, 77), in murine models
(57), and in ex vivo (27, 53, 57, 58) studies, with modifications
of the osteonic balance in favour of osteoblastic activity. Borte-
zomib could also exert a direct stimulatory effect on os-
teoblasts (58), and an inhibitory one on osteoclasts (77). As ex-
pected result, the treatment with bortezomib should lead to a
significant improvement of deranged bone turnover, indirectly
measurable with biochemical parameters as the ones cited
above. A few recently conducted studies have actually demon-
strated that treatment with bortezomib not only results in lower-
ing OAFs and osteoclast activity markers, but also in raising
pro-osteoblastic soluble factors and osteoblast function serum
markers (52, 54-57, 59, 78). These studies looked for various
markers modifications in the course of regimens containing
bortezomib, either alone or combined with other drugs (54, 55).
Some of them were group-controlled: age matched healthy
subjects (56) or patients treated with non-bortezomib-contain-
ing schemes (78). The results tend to confirm the “pro-os-
teoblastic” in vitro activity of bortezomib, even though a major
pitfall of these studies is that they could not directly measure
modifications in bone quality. In this regard, an exception is a
clinical work by Giuliani et al. (58), in which osteoblasts and
their precursors were found to be increased in number, as di-
rectly assessed in bone marrow biopsies obtained from pa-
tients that had undergone treatment with bortezomib. 
Conclusions
MM has profound effects on bone metabolism. The very nature
of this incurable disease leads to the severe and disabling
bone complications that afflict MM patients. Apart from target-
ing MM cells directly, blocking bone destruction must be a ma-
jor goal in therapy. Ideally, treatment should be aimed in eradi-
cating neoplastic cells, but since this is almost impossible in
most patients, restoring normal bone turnover would still be a
step forward in treatment. Bisphosphonates have an important
role in MM bone disease, but their activity is mainly directed to-
wards blocking osteoclastic activity. These drugs do not en-
hance osteoblastic functions, which are impaired in MM. The
discovery of bortezomib in vitro properties has prompted a
great interest in research. However, in vivo evaluation of borte-
zomib “pro-osteoblastic” activity must take into account several
difficulties, and raises many questions: first of all, which tech-
nique is the most suitable in the assessment of patients’ “bone
quality” before and after treatment with bortezomib? Dual
Emission X-Ray Absorptiometry (DEXA) is the standard for
measuring bone density in patients with osteoporosis, but it is
not sensible enough to observe subtle density modifications
during the few months of treatment with bortezomib. Moreover,
sampling areas could be infiltrated by MM lesions, thus making
DEXA not reliable for routinary use in patients affected by MM
(46). New imaging technologies, like quantitative ultrasound,
quantitative computed tomography, peripheral quantitative to-
mography, micro-computed tomography, and magnetic reso-
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nance (79) are neither widely available nor standardized yet.
Direct count of osteoblasts and their precursors in biopsies ob-
tained from the patients treated with bortezomib seems to be
the most precise and reliable search performed so far (58). An-
other problem to be considered when planning studies aimed
in assessing bone quality modifications before and after treat-
ment with drugs like bortezomib is the choice of the patients to
enroll: including patients that were already pre-treated with
many drugs, or that did not receive similar doses of corticos-
teroids and bisphosphonates, introduces heavy biases in the
study itself, and this could bear unreliable and not easily inter-
pretable data. A last, but not less important doubt rises from
the real importance of dosing some (but which ones?) of the
newly discovered soluble factors involved in bone metabolism.
Do they, and if so, which ones, really correlate with modifica-
tions of “bone quality”? May they have a value in the prognostic
assessment or in the follow-up of patients affected by MM? In
conclusion, many molecules have been recently found to be in-
volved in normal and pathologic bone turnover, and to be al-
tered in MM natural course and during treatment. It may be that
new proteasome inhibitors like bortezomib retain a distinct ac-
tivity in bone “reverse remodelling”, not typical of other drug
classes currently used in MM treatment. Further studies are
needed to elucidate the usefulness of dosing bone metabolism
soluble molecules in patients treated with this new drug, to
clarify the molecular bases of bortezomib properties, and to as-
sess the clinical impact of its supposed “pro-osteoblastic” ac-
tion. Should this last assumption prove to be true in vivo, re-
search will have to focus, in the near future, on the develop-
ment of new bortezomib-like agents, targeted not only at block-
ing MM disease, but also at promoting the normalization of the
deranged bone turnover, which is so dramatically altered in this
severe and incurable neoplasia. 
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